检索历史 清除

目的 分析卵巢上皮性癌(卵巢癌)患者在初次治疗的不同阶段血清CA125水平与卵巢癌复发和预后的关系.方法 收集2002年1月-2005年12月间浙江大学医学院附属妇产科医院经病理检查证实的151例原发性卵巢癌患者的临床病理资料并进行随访,分析初次治疗的不同阶段血清CA125水平与临床病理参数、2年复发率和5年复发率、5年生存率及无瘤生存期和总生存期的相关性.结果 卵巢癌患者术前血清CA125水平、化疗3个疗程结束时CA125是否降为正常与大多数预后相关的临床病理参数相关,包括分期、病理分级、腹水量、残留病灶大小、复发类型、2年复发率、5年复发率及5年生存率(P均＜0.05).术前及化疗3个疗程结束时血清CA125水平与无瘤生存期和总生存期呈显著性相关(P均＜0.01).但未见手术前后CA125下降幅度与复发和预后的相关性(P均＞0.05).结论 术前及化疗3个疗程结束时血清CA125水平可用于预测卵巢癌的复发和预后.

Objective To analyze the association of serum CA125 level at the different phases with recurrence and survival, for providing simple and efficient methods about predicting recurrence and prognosis in epithelial ovarian cancer.Methods The clinical-pathological data from 151 patients were collected, who were histologically confirmed as primary ovarian cancer between Jan 2002 and Dec 2005.All the patients were followed up.The relationship between serum CA125 level at different phases and clinical-pathological data were analyzed, including prognostic associated factors, 2-year or 5-year recurrent rate, 5-year survival rate, progression-free survival times, and overall survival times.Results Serum CA125 level at pre-surgery and the end of 3-course chemotherapy were associated with most of the clinical-pathological parameters,included stage, pathological grade, amount of ascites, residual tumor size, type of recurrence, 2-year and 5-year recurrent rate, and 5-year survival rate ( all P ＜ 0.05 ).Progression-free survival and overall survival times were shorter in the patients with higher CA125 level at pre-surgery or abnormal CA125 level at the end of 3-course chemotherapy (P ＜0.01 ).There was no relationship between the ratio of CA125 level at pre- and post-surgery and recurrence or prognosis ( all P ＞ 0.05).Conclusion Serum CA125 level at pre-surgery and the end of 3-course chemotherapy can be used for predicting the recurrence and prognosis of epithelial ovarian cancer.